1. Home
  2. GPOR vs ACAD Comparison

GPOR vs ACAD Comparison

Compare GPOR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gulfport Energy Corporation

GPOR

Gulfport Energy Corporation

HOLD

Current Price

$216.66

Market Cap

4.1B

Sector

Energy

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$26.59

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPOR
ACAD
Founded
1997
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
GPOR
ACAD
Price
$216.66
$26.59
Analyst Decision
Buy
Buy
Analyst Count
10
21
Target Price
$221.22
$29.24
AVG Volume (30 Days)
259.7K
1.6M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
N/A
1.54
Revenue
$1,231,668,000.00
$1,047,118,000.00
Revenue This Year
$57.17
$15.16
Revenue Next Year
$8.75
$11.42
P/E Ratio
N/A
$16.79
Revenue Growth
38.91
12.69
52 Week Low
$153.27
$13.40
52 Week High
$225.78
$26.65

Technical Indicators

Market Signals
Indicator
GPOR
ACAD
Relative Strength Index (RSI) 60.91 72.80
Support Level $212.34 $22.81
Resistance Level $225.78 $25.20
Average True Range (ATR) 6.90 0.85
MACD -0.27 0.24
Stochastic Oscillator 61.17 99.25

Price Performance

Historical Comparison
GPOR
ACAD

About GPOR Gulfport Energy Corporation

Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: